- Home
- KZR vs MRSN Comparison
KZR vs MRSN Comparison
Compare KZR & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- MRSN
- Stock Information
- Founded
- KZR 2015
- MRSN 2001
- Country
- KZR United States
- MRSN United States
- Employees
- KZR N/A
- MRSN N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- KZR Health Care
- MRSN Health Care
- Exchange
- KZR Nasdaq
- MRSN Nasdaq
- Market Cap
- KZR 29.7M
- MRSN 32.9M
- IPO Year
- KZR 2018
- MRSN 2017
- Fundamental
- Price
- KZR $4.01
- MRSN $6.30
- Analyst Decision
- KZR Hold
- MRSN Strong Buy
- Analyst Count
- KZR 2
- MRSN 5
- Target Price
- KZR $9.00
- MRSN $143.75
- AVG Volume (30 Days)
- KZR 81.6K
- MRSN 117.6K
- Earning Date
- KZR 08-19-2025
- MRSN 08-13-2025
- Dividend Yield
- KZR N/A
- MRSN N/A
- EPS Growth
- KZR N/A
- MRSN N/A
- EPS
- KZR N/A
- MRSN N/A
- Revenue
- KZR N/A
- MRSN $34,006,000.00
- Revenue This Year
- KZR N/A
- MRSN N/A
- Revenue Next Year
- KZR N/A
- MRSN $1.03
- P/E Ratio
- KZR N/A
- MRSN N/A
- Revenue Growth
- KZR N/A
- MRSN N/A
- 52 Week Low
- KZR $3.62
- MRSN $6.22
- 52 Week High
- KZR $9.18
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- KZR 38.90
- MRSN 37.15
- Support Level
- KZR $3.98
- MRSN $6.37
- Resistance Level
- KZR $4.23
- MRSN $7.05
- Average True Range (ATR)
- KZR 0.19
- MRSN 0.54
- MACD
- KZR -0.04
- MRSN -0.13
- Stochastic Oscillator
- KZR 9.56
- MRSN 1.99
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.